Hørsholm, Denmark — Visiopharm, a world leader in AI-driven precision pathology, is thrilled to become a preferred partner to PathAI with the integration of its precision pathology APPs into the AISight^Ⓡ1 Image Management System (IMS). This partnership underscores Visiopharm’s commitment to transforming diagnostic and translational pathology workflows by enabling PathAI’s AISight IMS users to analyze images with unparalleled accuracy and speed.

Visiopharm offers a comprehensive suite of diagnostic APPs, including a breast panel (HER2, ER, PR, metastasis detection, and Ki-67), and a non-small cell lung cancer (PD-L1) APP. These APPs are IVDR-cleared for use in the EU and UK and designated for research use in other regions. These tools will empower pathology laboratories with high-performance algorithms designed to streamline workflows and enhance diagnostic precision.

PathAI’s AISight IMS is designed to enhance interoperability and efficiency in digital pathology. Laboratories using AISight can seamlessly access a diverse portfolio of digital pathology algorithms from leading global AI providers, including Visiopharm. Pathologists will benefit from rich visual support, including AI-generated overlays and embedded quantitative results, driving more informed decision-making and differentiated workflows.

“We are excited to collaborate with Visiopharm and integrate their leading AI image analysis technologies into our AISight platform,” said Andy Beck, CEO of PathAI. “This partnership reinforces our mission to provide pathologists with comprehensive, state-of-the-art tools that enhance precision and increase workflow efficiency in the pathology laboratory. By incorporating Visiopharm’s innovative solutions, we are broadening access to top-tier AI capabilities, ultimately driving better patient outcomes and setting a new standard in digital pathology.”

Michael Grunkin, CEO of Visiopharm, expressed his enthusiasm about the partnership: “We are delighted to collaborate with PathAI to bring our portfolio of fully automated AI-driven diagnostic and translational solutions for breast and lung cancer to a broader audience. Our commitment is to expand access to precision pathology on leading platforms. Becoming ​​​​a preferred partner for PathAI’s AISight Image Management System is an important step towards this goal. With our platform-agnostic technology designed for seamless integration, we look forward to working closely with the PathAI team to accelerate the adoption of digital pathology worldwide, ultimately enhancing lab efficiency and improving the quality of patient care.”

​​Pathology laboratories worldwide are invited to experience the power of Visiopharm’s precision pathology APPs on PathAI’s AISight IMS. To schedule a demonstration of the APPs, please contact us at https://visiopharm.com/. ​​

​​​​​ 

​​​¹AISight is for Research Use Only in the US; AISight Dx is CE-IVDR in Europe and UKCA in UK​​ 

About Visiopharm 

Visiopharm is a leading provider of AI-driven precision pathology software for research and diagnostics. In research, it is a technology leader providing tools that help scientists, pathologists, and image analysis experts produce accurate data for all types of tissue-based research. In diagnostics, it is a leader within clinical applications, with no fewer than nine diagnostic algorithms cleared under IVDR for EU and UK customers. These applications provide diagnostic decision support and can be easily activated and integrated into existing lab workflows. Founded in 2002, Visiopharm is privately owned and operates internationally with over 750 customer accounts in more than 40 countries. The company’s headquarters are located in Denmark’s Medicon Valley, with legal entities in Sweden, the UK, Germany, the Netherlands, and the United States, and local representation in France and China.

For more information visit visiopharm.com. 

About PathAI
PathAI is a global leader in AI-powered digital pathology solutions, dedicated to improving operational efficiency in pathology labs worldwide. Through its innovative technology and strategic partnerships, PathAI is shaping the future of medical diagnostics and advancing patient care across the globe.

Los Angeles, CA – Molecular Instruments® (MI), the inventor of the HCR™ Imaging technology, is pleased to announce a strategic partnership with Visiopharm, a global leader in AI-driven precision pathology software. This collaboration brings together MI’s clinical-grade HCR™ platform with Visiopharm’s Oncotopix® Discovery software, empowering users with a highly flexible, deep learning approach to precise and efficient image analysis for RNA-ISH assays.

MI’s class-leading HCR™ Pro RNA-ISH assay, lauded for making protease-free sample preparation the standard for RNA-ISH, provides unparalleled specificity and sensitivity in RNA detection and enables seamless integration with existing IHC/IF workflows. When combined with Oncotopix® Discovery, researchers can analyze chromogenic and fluorescent HCR™ Pro RNA-ISH and HCR™ Pro RNA-ISH + IHC/IF co-detection images with more precise segmentation and spot counting, ensuring accurate gene expression profiling in even the most challenging samples.

“Our North Star at MI is to set bioimaging assays to a true ‘clinical-grade’ standard, focusing on performance, robustness, and accessibility,” said Dr. Aneesh Acharya, Chief Commercial Officer at Molecular Instruments. “Partnering with Visiopharm reflects our shared drive to delivering clinical-grade assays, paired with world-class analysis tools that empower pathologists and support decision-making. We’re thrilled to kickstart this journey with the team at Visiopharm to bring new possibilities to RNA-ISH.”

Visiopharm’s Oncotopix® Discovery software enables users to explore complex tissue data intuitively and customize analyses to fit their specific experimental needs. Its advanced exploratory capabilities enhance analysis accuracy in complex tissue samples. The ability to develop custom deep-learning-based segmentation algorithms, which can account for both cellular and nuclear morphology, enables more precise quantification of RNA. This marks a significant improvement over traditional methods, which often struggle with complex or irregular structures, such as anuclear or multinucleate cells, leading to missed or inaccurate counts.

“At Visiopharm, our mission is to empower researchers with advanced tools that deliver unmatched precision in image analysis,” said Regan Baird, Senior Vice President, Commercial Strategy Deployment of Visiopharm. “Partnering with Molecular Instruments allows us to elevate the standard of RNA-ISH analysis, integrating our Oncotopix® Discovery software with MI’s HCR™ technology to provide researchers with an unprecedented level of accuracy and efficiency. We are excited to collaborate and advance the field of precision pathology, accelerating breakthroughs in disease research and diagnostics.”

This partnership marks a pivotal advancement in research, combining high-performance, clinical-grade RNA-ISH with sophisticated image analysis. Together, we are equipping scientists to drive breakthroughs in disease studies, offering deeper insights into gene expression and protein interactions. By integrating our innovative technologies, we aim to accelerate discoveries across translational medicine, where accurately and precisely understanding gene and protein expression are essential.

About Visiopharm:  

Visiopharm is a leading provider of AI-driven precision pathology software for research and diagnostics. In research, it is a technology leader providing tools that help scientists, pathologists, and image analysis experts produce accurate data for all types of tissue-based research. In diagnostics, it is a leader within clinical applications, with no fewer than nine diagnostic algorithms cleared under IVDR for EU and UK customers. These applications provide diagnostic decision support and can be easily activated and integrated into existing lab workflows. Founded in 2002, Visiopharm is privately owned and operates internationally with over 750 customer accounts in more than 40 countries. The company’s headquarters are located in Denmark’s Medicon Valley, with legal entities in Sweden, the UK, Germany, the Netherlands, and the United States, and local representation in France and China.  

For more information visit visiopharm.com.

About Molecular Instruments:  

Molecular Instruments® (www.hcrimaging.com) develops and synthesizes molecular kits powered by the breakthrough HCR™ imaging platform for applications in academic research, drug development, synthetic biology, and clinical pathology and diagnostics.